Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Biotech's blue shift

The biotech downdraft is having an ugly side effect outside of losing investors a lot of money: It's drastically reducing the number of "investable" biotech companies.

Wall Street typically considers any company with a market capitalization of less than $1 billion to be small cap, and many mutual funds have charters that keep them out of that space. As biotech valuations accelerated during the red shift of the genomics bubble,

Read the full 701 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE